Odyssey Thera Inc has collaborated with the leading Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation for the analysis of drug candidates from a number of Mitsubishi Tanabe preclinical programmes. Odyssey also announced the issuance of Japanese patent number JP 4262778, entitled 'Protein fragment complementation assays for the detection of biological or drug interactions'.
"We look forward to applying our patented human cell analysis technologies and proprietary drug profiling strategies to enhance Mitsubishi Tanabe's promising drug discovery programmes," said Dr John Westwick, president and CEO of Odyssey Thera. "Our partnership with Mitsubishi Tanabe and the issuance of our Japanese patent reflect our objective of making our unique knowledge base and enabling technologies available to quality partners around the globe."
Odyssey Thera will apply its patented Protein-fragment Complementation Assay (PCA), proprietary High Context Screening infrastructure, unique institutional knowledge, and state-of-the-art data analysis strategies in the collaboration to yield valuable insights related to drug selectivity, safety, and mechanisms of action. Financial terms of the collaboration were not disclosed.
Odyssey Thera is a drug discovery company committed to identifying novel drug candidates for oncology and other chronic diseases.